Skip to main content
. 2021 Sep 28;97(13):e1276–e1287. doi: 10.1212/WNL.0000000000012598

Figure 1. Prevalence of Neuropsychiatric Symptoms (NPS) Across a β-Amyloid–Positive (A+) Sample According to Clinical Alzheimer Disease (AD) Stage.

Figure 1

*p < 0.05 after correcting for false discovery rate. **p < 0.01 after correcting for false discovery rate. ***p < 0.001 after correcting for false discovery rate. AMB = aberrant motor behaviors; MCI = mild cognitive impairment; SCD = subjective cognitive decline.